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The 2014 World Health Organization (WHO) classiﬁcation of endometrial hyperplasia (EH) deﬁnes premalignant EH
based on only cytologic atypia, disregarding architecture complexity. We aimed to assess the impact of architecture
complexity on the risk of cancer in non-atypical EH. A systematic review and meta-analysis was performed by
searching electronic databases form their inception to October 2018. All studies assessing the rates of progression to
cancer in non-atypical EH (simple vs complex) were included. Pooled relative risk (RR) for cancer progression was
calculated; a p-value < 0.05 was considered signiﬁcant. Eight studies with 1066 women were included. The risk for
progression of non-atypical EH to cancer was signiﬁcantly higher in complex EH than in simple EH (p < 0.0001),
with an RR of 4.90. In conclusion, the complexity of glandular architecture signiﬁcantly increases the risk of cancer
in non-atypical EH. Complex non-atypical EH may be regarded as a low-risk premalignant lesion rather than a
benign condition.
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endometrial precancer; atypical endometrial hyperplasia.
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Endometrial hyperplasia (EH) is an irregular prolif-
eration of endometrial glands, which can coexist with
or progress to endometrial cancer (1, 2). The risk of
cancer is highly variable in EH. Before 2014, the
World Health Organization (WHO) classiﬁcation
had considered complexity of glandular architecture
and cytologic atypia as the crucial morphologic fea-
tures in EH, in order to determine the risk of pro-
gression to cancer (2–4). The EH had been
categorized as ‘simple EH without atypia’ (S-EH,
low risk), ‘complex EH without atypia’ (C-EH, inter-
mediate risk) or ‘atypical EH’ (A-EH, high risk) (4).
However, it has been shown that EH actually
has a dual nature: some EH are polyclonal prolifer-
ations, reactive to an unopposed action of estro-
gens, while other EH are monoclonal and
constitute the precursor of endometrioid adenocar-
cinoma (1–3). The diﬀerential diagnosis between
benign and premalignant EH is crucial for the
patient management. Indeed, benign EH may be
followed without any treatment when asymp-
tomatic; otherwise, progestins may be used. On the
other hand, premalignant EH requires hysterec-
tomy; in selected cases (wish to preserve fertility,
contraindication for surgery), a conservative treat-
ment can be chosen, using progestins alone or in
combination with hysteroscopic resection (5–7).
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The current WHO classiﬁcation (2014) deﬁnes A-
EH as a premalignant lesion. On the other hand,
EH without atypia is deﬁned as benign, lumping
together S-EH and C-EH (1). In spite of this, there
is evidence that a signiﬁcant fraction of C-EH may
actually be precancerous lesions (8). Considering
these lesions as benign may lead not to treat the
patients, with a risk of progression to cancer.
In this study, we aimed to deﬁne the prognostic
signiﬁcance of the complexity of EH glandular
architecture in the absence of cytologic atypia, by
comparing the risk of progression to cancer in S-
EH vs C-EH.
MATERIALS AND METHODS
Study protocol
Methods for data collection, risk of bias assessment, data
extraction and data analysis were designed a priori. All
review stages were conducted independently by two
reviewers (AT, AR). Disagreements were resolved by dis-
cussion with a third reviewer (GS).
The study was reported following the Preferred Report-
ing Item for Systematic Reviews and Meta-Analyses
(PRISMA) statement (9).
Search strategy
MEDLINE, Scopus, Web of Science, EMBASE, Clini-
calTrials.gov, OVID, Cochrane Library and Google Scho-
lar were searched for relevant articles from the inception
of each database to October 2018. Several researches were
made by using a combination of the following text words
found on Medical SubHeading (MeSH) vocabulary: ‘en-
dometr*’; ‘hyperplas*’; ‘intraepithelial neoplasia’; ‘precan-
cer’; ‘premalignant’; ‘precursor’; ‘WHO’; ‘EIN’; ‘WHO’;
‘cancer’; ‘carcinoma’; ‘adenocarcinoma’; ‘predict*’; ‘prog-
nos*’; ‘progress*’; ‘develop*’; ‘risk’. References from rele-
vant articles were also reviewed.
Study selection
We included all peer-reviewed, retrospective or prospective
studies assessing the rates of progression to cancer sepa-
rately for S-EH and C-EH.
Exclusion criteria, deﬁned a priori, were:
1. assessment of only EH that underwent hysterectomy
as primary treatment;
2. reviews;
3. same cohort of patients as a study had already
included.
Risk of bias within studies assessment
The revised Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) was used to assess the risk of bias
within studies (10). The risk of bias was assessed in each
study for four domains: (i) patient selection (if patients
were consecutively selected); (ii) index diagnosis (if
endometrial sampling was performed with the same
method for all patients), (iii) reference diagnosis (if the
progression to cancer was conﬁrmed on a subsequent
hysterectomy), (iv) ﬂow and timing (if all patients were
followed for at least one year, as the EC diagnosed
within one year from the index diagnosis are usually
considered as ‘coexistent’ rather than subsequently
developed (11, 12)). For each domain, authors’ judg-
ments were ‘low risk’, ‘high risk’ or ‘unclear risk of bias’
if the data regarding the domain were ‘reported and ade-
quate’, ‘reported but inadequate’ and ‘not reported’,
respectively.
Data extraction
Data were extracted from each study without modiﬁca-
tions and reported in 2 9 2 contingency tables. Two
dichotomous qualitative variables were reported in the
tables:
EH category (‘S-EH’ or ‘C-EH’);
progression to cancer (‘no cancer’ or ‘cancer’).
Data analysis
The impact of glandular complexity on the risk of cancer
was assessed by calculating the relative risk (RR) for pro-
gression to cancer. Values were reported for each study
and as pooled estimate on forest plots, with 95% conﬁ-
dence interval (CI). A p-value < 0.05 was considered sig-
niﬁcant.
Statistical heterogeneity among studies was quantiﬁed
by using the inconsistency index I2: heterogeneity was con-
sidered null for I2 = 0%, minimal for I2 < 25%, low for
I2 < 50%, moderate for I2 < 75% and high for I2 ≥ 75%.
The random eﬀect model of DerSimonian and Laird was
used only if I2 > 50%; otherwise, a ﬁxed-eﬀect model was
adopted.
Review Manager 5.3 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014) was
used for the analysis.
Risk of Bias across studies assessment
The risk of bias across studies was assessed by using a
funnel plot, reporting the several studies on a plan based
on RR values (on the x axis) and the standard error (on
the y axis). The risk of publication bias was signiﬁcant if
the funnel plot was asymmetrical and if the studies with
higher standard error (which indicate low study accuracy)
showed higher RR.
RESULTS
Selection and characteristics of the studies
Eight retrospective studies with a total of 1066 EH
without atypia were included (11–18). The whole
process of study selection is reported in Fig. 1.
Seven studies were designed as retrospective
cohorts and one as case-control. Endometrial sam-
pling was performed by curettage in most studies;
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other methods included vacuum aspiration, Pipelle
biopsy and hysteroscopic biopsy.
Characteristics of the included studies are
reported in Table 1.
Risk of bias within studies assessment
For the ‘patient selection’ domain, one study was
considered at high risk of bias due to its design
(case-control with oversampling of A-EH (12)),
which makes it unsuitable for comparison with
other studies.
For the ‘index diagnosis’ domain, three studies
were considered at unclear risk, because the index
sampling method was not speciﬁed or not uniform.
For the ‘reference diagnosis’ domain, six studies
were considered at unclear risk, because it was not
stated whether all cancer diagnoses were conﬁrmed
on hysterectomy specimens.
For the ‘ﬂow and timing’ domain, two studies
were considered at unclear risk, since patients with
a follow-up < 1 year were also included.
All remaining judgments for each domain were
at ‘low risk of bias’. Results of the risk of bias
assessment are shown in Fig. 2.
Meta-analysis
Seven studies were included in the meta-analysis;
the study at high risk of bias was excluded.
Fig. 1. Flow diagram of studies identiﬁed in the systematic review (Prisma template [Preferred Reporting Item for System-
atic Reviews and Meta-Analyses]).
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The risk for progression to cancer was signiﬁ-
cantly higher in C-EH than in S-EH (p < 0.0001),
with an RR or 4.90 (96% CI: 2.21–10.86). Hetero-
geneity among studies was completely absent
(I2 = 0%) (Fig. 3).
The funnel plot showed symmetric distribution
of RR values, indicating that the risk of publication
bias was not signiﬁcant (Fig. 4).
DISCUSSION
Main findings and interpretations
Our study showed that, in the absence of cytologic
atypia, the complexity of glandular architecture sig-
niﬁcantly increases the risk of progression of EH to
cancer, with a risk increase of almost 5-fold.
The diagnosis of EH is a long-standing issue.
Before the 1994 WHO classiﬁcation, there was no
univocal system for EH categorization. One of the
most used systems had classiﬁed EH into ‘cystic
glandular’ (increased gland-to-stroma ratio without
signiﬁcant crowding, cystically dilated glands), ‘ade-
nomatous’ (closely packed glands with irregular
proﬁle) and ‘atypical adenomatous’ (with superim-
posed cytologic atypia) (4). The 1994 WHO classiﬁ-
cation, based on a large study by Kurman et al.,
had classiﬁed EH according to two crucial
parameters: complexity of glandular architecture
and cytologic atypia, deﬁning four categories of
EH: ‘simple non-atypical’, ‘complex non-atypical’,
‘simple atypical’ and ‘complex atypical’ (2, 13). The
category of ‘simple atypical EH’ did not correspond
to any previous category and was removed in the
2003 revision, returning to a triple classiﬁcation
into ‘S-EH’, ‘C-EH’ and ‘A-EH’ (4). Alongside
WHO, an alternative classiﬁcation system was
developed, the Endometrial Intraepithelial Neo-
plasia (EIN) system. The EIN system arose from
morphometric and molecular studies in the 1980s
and 1990s, which showed that EH actually had a
dual nature. Indeed, some EH are polyclonal, dys-
functional proliferation, while other ones are true
precancerous lesions. The EIN system separates EH
into ‘benign EH’ and ‘EIN’, based on the presence
of three morphologic parameters: glandular crowd-
ing, lesion diameter > 1 mm and cytology diﬀerent
from adjacent endometrium. The EIN system has
outlined that premalignant EH arise as a focal
lesion, distinct from the background endometrium,
while benign EH is diﬀuse (2, 3, 19). Given the sci-
entiﬁc impact of EIN system, in 2014 the WHO
had proposed a dual classiﬁcation of EH into ‘non-
atypical’ and ‘atypical’. The 2014 classiﬁcation
reports ‘A-EH’ and ‘EIN’ as synonyms, adopting
the same conceptual basis as the EIN system (1).
Table 1. Characteristics of the included studies. C: patient with coexistent cancer; N: patient with no coexistent cancer
Study Country Institute Design Period
of
enrollment
Total
sample
size
Sample
of
interest
Patients
age
(mean)
Sampling
method
Classiﬁcation
adopted
Follow-up
(mean)
Progression
diagnosis
Kurman
et al.
(1985)
(13)
USA Armed
Forces
Institute of
Pathology
Retrospective
cohort
1940–1970 170 122 17–71 Curettage WHO 1–27 years (13) Variable
Baak
et al.(1992)
(14)
Nether-
lands
University
Hospital,
De
Boelelaan
Retrospective
cohort
<1985 39 14 (53)C
(40)N
Curettage WHO, EIN 6–52
months (17)C
(32 months)N
Hysterectomy
Orbo
et al. (2000)
(15)
Norway University
Hospital
of Tromsø
Retrospective
cohort
1980–1991 68 19 28–77
(48)
Curettage WHO, EIN 3–39
months (7)C
2–21 yearsN
Hysterectomy
Baak et al.
(2001)
(16)
Nether-
lands,
Norway
Multicentre Retrospective
cohort
1988–1998 132 71 34–77
(58)C
20–93
(50)N
Curettage WHO, EIN 1–10 years
(not excluding
earlier cancers)
n.r.
Baak et al.
(2005)
(11)
Europe,
America
Multicentre Retrospective
cohort
22 years
period
(un-
speciﬁed)
674 467 n.r. Curettage,
aspiration,
Pipelle
WHO, EIN 13–120
months (48)C
13–216
months (68)N
n.r.
Hecht et al.
(2005)
(17)
Israel Beth Israel
Hospital
Retrospective
cohort
1998–2000 97 63 n.r. Biopsies,
curettages
WHO, EIN At least 1
year (not
excluding
earlier cancers)
Variable
Lacey
et al. (2008)
(12)
USA Kaiser
Permanente
Northwest
Department
of
Pathology
Case-control 1970–2002 379 170 n.r. n.r. WHO, EIN At least 1
year (68 days)
hysterectomized
(3 years)
others
n.r.
Steinbakk
et al.
(2011) (18)
Norway Stavanger
University
Hospital
Retrospective
cohort
1980–2004 152 140 21–88
(53)
Curettage WHO, EIN 12–238
months (57)
n.r.
Total 1940–2004 1711 1066 – – – – –
WHO, World Health Organization; EIN, Endometrial Intraepithelial Neoplasia.
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However, the WHO 2014 terminology appears con-
founding, as it is unclear if the acronym ‘EIN’
(written in full as ‘endometrioid intraepithelial neo-
plasia’) actually refers to the EIN (endometrial
intraepithelial neoplasia) system. In fact, the current
WHO classiﬁcation is not well integrated with EIN
criteria, but it appears based on the only one
parameter of cytologic atypia, which includes
nuclear enlargement, pleomorphism, rounding, loss
of polarity and nucleoli (19). On the other hand,
the EIN system takes into account the presence of
glandular crowding, which is a crucial feature in C-
EH. Furthermore, the irregularity of glandular
proﬁle observed in C-EH has been a major parame-
ter in morphometric analyses underlying the EIN
system (3).
Although the EIN system has been reported to
outperform the WHO system in the risk
Fig. 2. (A) Assessment of risk of bias. Summary of risk of bias for each study; plus sign: low risk of bias; minus sign: high
risk of bias; question mark: unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percent-
ages across all included studies.
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stratiﬁcation of EH, most of these results regard
the objective assessment of EIN criteria, based on a
computerized morphometric assessment, which is
not widely available (3, 11). On the other hand, the
superiority of the ‘subjective’ EIN system over the
WHO system is still the subject of debate (12).
In our previous studies, we investigated the
expression of Bcl-2, PTEN and PAX2 – three mole-
cules involved in endometrial carcinogenesis – in
EH. We found that, for Bcl-2 and PAX2, an aber-
rant expression correlated with EIN criteria of pre-
malignancy better than with the WHO criteria,
while no signiﬁcant diﬀerence was found for PTEN
(20–22). Furthermore, in another study we found
that the EIN system was more sensitive, but less
speciﬁc than the WHO one for the risk of cancer
coexistent with EH (19). In these studies, we postu-
lated that a major cause of the diﬀerence between
WHO and EIN system may lie in the ‘complex
non-atypical EH’ category. Indeed, it has been
shown that many C-EH meet EIN criteria of pre-
malignancy. Cytologic features of EIN may be only
slightly diﬀerent from normal endometrium, in the
absence of overt atypical features (nuclear rounding
and enlargement, loss of polarization, presence of
nucleoli). A delimited lesion > 1 mm, characterized
by glandular crowding, with minimal cytologic dif-
ference from adjacent endometrium, in the absence
of overt nuclear atypia, would fall in the benign
category according to the WHO system, and in the
premalignant category according to the EIN sys-
tem. This would explain both the higher sensitivity
and the lower speciﬁcity of EIN system compared
to the WHO one.
All these observations suggest that many C-EH
might be regarded as ‘low-risk’ premalignant lesion,
i.e. they are monoclonal, harbor the typical genetic
alteration of EC, but are in an early phase of car-
cinogenesis. Consistently, our current study showed
a 4.9-fold increase in the risk of progression to can-
cer, which is lower than the risk increase related to
atypical EH, but still signiﬁcant.
In order not to miss these premalignant lesions,
we have previously proposed an integration of the
WHO system with the EIN system. Basically, we
have suggested to use the EIN criteria to recognize
premalignant EH, substratifying them based on the
presence of overt cytologic atypia. According to
such an approach, three EH categories would be
identiﬁed: benign EH (polyclonal); EIN without
overt atypia (premalignant, but with lower risk of
cancer); EIN with overt atypia (premalignant, but
with higher risk of cancer) (19).
In our experience, endometrial biopsies with
cytologically ambiguous areas of crowded glands
are common. In these patients, a diagnosis of A-
EH/EIN may lead to hysterectomy, in particular if
they do not wish to get pregnant or if they were
already conservatively treated. On the other hand,
a diagnosis of benign EH might lead to undertreat-
ment with subsequent occult progression of the
lesion. In these cases, a diagnosis of ‘EIN without
overt atypia’, or low-risk premalignant lesion, may
Fig. 3. Forest plot reporting relative risk values for the risk of coexistent cancer in complex hyperplasia without atypia vs
simple hyperplasia without atypia, for each study and as pooled estimate, with 95% conﬁdence interval.
Fig. 4. Funnel plot for the assessment of the risk of bias
across studies, reporting relative risk on the x axis and
standard error (ER) on the y axis.
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indicate the need to treat and follow the patients,
in the absence of the imminent risk of cancer. Fur-
thermore, in women conservatively treated, the
aggressiveness of treatment (e.g., oral progestins,
intrauterine progestins, hysteroscopic resection plus
progestins) and the timing of follow-up might be
deﬁned according to the presence of overt atypia,
since molecular or immunohistochemical predictive
markers have shown little value (23, 24). Finally, in
women addressed to hysterectomy, the presence of
overt atypia might direct the surgical priority.
Such an approach may lead to a more tailored
management of women with EH.
Further studies are necessary to conﬁrm the use
of this combined classiﬁcation in the common prac-
tice and all its possible clinical implications.
Strengths and limitations
To the best of our knowledge, this is the ﬁrst meta-
analysis assessing the impact of the complexity of
EH glandular architecture on the risk of progres-
sion to cancer. Our analysis showed complete
absence of heterogeneity among studies, and
absence of publication bias, giving solidity to our
results. Furthermore, our ﬁndings are consistent
with the scientiﬁc evidence in this ﬁeld, as widely
discussed above.
Some limitations may aﬀect our results. The
duration of follow-up varies among studies. Some
authors included patients with a follow-
up < 1 year, creating a possible confusion between
progression of EH to cancer and coexistence of
cancer with EH. However, the presence of coexis-
tent cancer might have a signiﬁcance similar to the
progression to cancer, as it still identiﬁes EH at
higher risk.
Progression rates might also vary based on the
patient management (i.e., whether or not the
patient was treated before hysterectomy; which type
of progestin was administered; whether or not hys-
teroscopic resection was performed) (6, 7).
Furthermore, the low reproducibility of the diag-
nosis of EH and its morphologic parameters (archi-
tecture complexity, nuclear atypia) might be a
major limitation, despite being intrinsic to the topic
assessed (25).
CONCLUSION
The complexity of glandular architecture increases
the risk of cancer in EH independently from the
presence of overt cytologic atypia. Despite being
considered benign by the current WHO classiﬁca-
tion, the category of ‘complex non-atypical EH’
includes many monoclonal lesions, which may be
regarded as low-risk premalignant lesions. The EIN
system might be useful not to miss these precancers,
which may be referred to as ‘EIN without overt
atypia’ or ‘low-risk EIN’. Further studies are neces-
sary to conﬁrm the validity of such approach.
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